How FDA’s Prior-Knowledge Strategy Is Reshaping Global Cell and Gene Therapy Development

Executive Summary

The U.S. Food and Drug Administration (FDA) has introduced new draft guidance permitting developers of cell and gene therapies to leverage "prior knowledge" and "platform knowledge" in their regulatory submissions, potentially reducing development timelines and costs. This move aligns with a broader regulatory trend in the United States to streamline approval pathways, including reduced reliance on animal testing and expanded use of priority review vouchers. For global stakeholders, these changes carry significant implications for biotech investment, innovation competitiveness, and international regulatory convergence.

Introduction

The biopharmaceutical industry operates in an era of rapid scientific advancement and intense global competition. Regulatory agility has become a strategic asset. In early June 2026, the FDA released two key draft guidance documents that could fundamentally alter how cell and gene therapies and cancer biologics are developed. These initiatives, part of a year-long policy shift at the agency, are not just domestic administrative updates; they represent a competitive signal to the world that the United States intends to remain at the forefront of advanced therapeutic innovation. Understanding the global impact of these changes is essential for executives, investors, and policymakers.

Background & Context

Throughout 2025, the FDA underwent significant change, with an emphasis on expediting drug development. The introduction of new accelerated pathways and the expansion of the Commissioner’s National Priority Voucher (CNPV) program were notable. However, these changes were not without controversy. Vaccine policy revisions by Health Secretary Robert F. Kennedy Jr. prompted resistance, and concerns about the politicization of the agency have emerged.

Amid this turbulence, the FDA has continued to issue guidance aimed at removing bottlenecks for advanced therapies. The new draft guidance on prior knowledge is particularly noteworthy because it acknowledges that the growing field of cell and gene therapy has amassed a substantial public body of knowledge that can be reused, avoiding duplication of effort and reducing regulatory burden.

Main Analysis

Leveraging Prior Knowledge

The FDA’s draft guidance, published June 2, outlines how sponsors can use "generally accepted scientific knowledge" and "platform knowledge" in their submissions. This includes manufacturing information, non-clinical data, clinical evidence, and analytical methods. For example, a company developing a new gene therapy could refer to published studies on similar vectors or manufacturing processes, provided it justifies the applicability to its own product.

This approach mirrors advances in other industries, where modular, standardized components accelerate innovation. In biotech, it could shorten timelines from years to months and reduce the cost of bringing therapies to market. The guidance also extends to "platform knowledge," which encompasses mechanisms of action, delivery modes, and manufacturing processes—information that can be derived from related products within the same company or the public domain.

Reducing Animal Testing

Another draft guidance, released May 29, aims to eliminate "unnecessary" animal testing for cancer biologics. The FDA now recommends single-species toxicology studies when possible and introduces a "Weight of Evidence" risk assessment that incorporates pharmacodynamic, pharmacokinetic, and literature-based data. This shift aligns with global trends in bioethics and could lower barriers to development, particularly for smaller biotech companies with limited resources.

Psychedelics and Priority Vouchers

In April, President Trump signed an executive order directing the FDA to grant Commissioner’s National Priority Vouchers to appropriate psychedelic drugs with Breakthrough Therapy designation. This could shorten review periods to as little as one to two months, creating new investment opportunities in mental health therapies. While controversial, this policy demonstrates the government’s willingness to use regulatory tools to accelerate innovation in areas with high unmet medical need.

RMAT Designation Flexibility

Earlier in March, the FDA revised its standard operating procedures to allow Regenerative Medicine Advanced Therapy (RMAT) designation for products on clinical hold. This change may benefit companies that have paused trials for safety or other reasons, offering a pathway to maintain regulatory momentum.

Global Impact

The global implications of these FDA policies are substantial. The United States remains a bellwether for drug regulation, and other regulators often align their frameworks accordingly. By embracing prior knowledge, the FDA signals that regulatory science can evolve to match technological progress. This could encourage global harmonization efforts, particularly with the European Medicines Agency and regulators in Asia, which may adopt similar approaches to attract investment and ensure patient access.

For multinational companies, the ability to use prior knowledge could streamline global development programs, reducing duplication across regions and enabling faster worldwide launch. It also affects foreign direct investment into US biotech, as falling regulatory risk enhances the attractiveness of the American market. Conversely, companies operating in jurisdictions with slower regulatory adaptation may face competitive disadvantages, prompting calls for international cooperation.

The reduction in animal testing could also influence global supply chains for laboratory animals and related services, shifting investment toward in silico modeling and other technologies.

Strategic Insights

Investment Opportunities

Investors should regard these regulatory changes as a catalyst for cell and gene therapy companies. Faster development translates into earlier commercialization and revenue generation, improving risk-adjusted returns. Platform-based companies that can leverage prior knowledge across multiple products are particularly well-positioned. The psychedelics sector may see a resurgence as the CNPV program de-risks late-stage clinical trials.

Policy Priorities

For governments and regulators worldwide, the FDA’s approach highlights the need to innovate in regulatory science. Outdated requirements can be a trade barrier. Countries seeking to expand their biotech ecosystems should consider similar measures to attract research and development and manufacturing investment.

Competitive Risks

The acceleration of US drug development could widen the gap between innovative and imitative markets. Emerging biotech hubs in Asia and Europe must adapt or risk falling behind. Additionally, concerns about regulatory politicization could erode trust, particularly if policies are perceived as driven by ideology rather than science. International stakeholders must monitor these developments.

Future Outlook

Over the next three to ten years, the convergence of regulatory flexibility and technological innovation will redefine drug development. Artificial intelligence and digital simulation are likely to play a larger role in the "prior knowledge" framework, enabling virtual submission packages. Global regulatory convergence may accelerate, with the FDA’s guidance serving as a template. However, geopolitical factors, including tensions between the US and China, could complicate harmonization.

The demand for cell and gene therapies is projected to grow, driven by aging populations and the rise of personalized medicine. Countries that embrace regulatory innovation will capture a larger share of this market. Conversely, those that maintain cumbersome processes may become marginal players.

Conclusion

The FDA’s use of prior knowledge to expedite cell and gene therapy development is a strategic move with global implications. It reduces barriers to innovation, transforms regulatory practice, and sends a clear message about the importance of advanced therapeutics. For global stakeholders, the imperative is to adapt—whether by adjusting investment strategies, updating policy frameworks, or enhancing international cooperation. The future of drug development is becoming faster and more collaborative, and the FDA has taken a decisive step toward that future.

Key Takeaways

• The FDA’s prior knowledge and platform knowledge guidance can significantly reduce development time and cost for cell and gene therapies.
• Reducing animal testing through Weight of Evidence assessments aligns with global ethical standards and lowers entry barriers.
• Priority voucher expansion for psychedelics may unlock rapid approvals for mental health treatments.
• Global regulators should consider similar flexibility to remain competitive in advanced therapeutic innovation.
• Investors should monitor platform-based companies and psychedelics developers as regulatory risk declines.

Sources

• BioSpace. (2026, June 3). FDA Policy Tracker 2026: FDA taps prior knowledge to expedite cell and gene therapy development. Retrieved from https://www.biospace.com/fda/fda-policy-tracker-2026-priority-vouchers-questioned-prvs-return